Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Trial Profile

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Tilsotolimod (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE 301
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2018 According to an Idera Pharmaceuticals media release, 42 of the planned up to 110 sites across 12 countries have been activated for the randomization of patients into the trial.
    • 22 Oct 2018 Planned End Date changed from 1 Jul 2020 to 1 Jun 2022.
    • 22 Oct 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Nov 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top